Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats: Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 3, 2007, Pages 147-154

  Kobayashi, Fumiyoshi ^a   Yageta, Yuichi ^a   Yamazaki, Takanobu ^a   Wakabayashi, Eiji ^a   Inoue, Masako ^a   Segawa, Mitsuru ^a   Matsuzawa, Shigeki ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anti cholinergics; CAS 170105 16 5; Imidafenacin; KRP 197; Morris water maze; ONO 8025; Overactive bladder; Salivary gland; Urinary bladder

Indexed keywords

CARBACHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DRUG VEHICLE; IMIDAFENACIN; KRP 197; MUSCARINIC M3 RECEPTOR ANTAGONIST; OXYBUTYNIN; PROPIVERINE; TOLTERODINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; BLADDER DISTENSION; BLADDER FUNCTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; FEMALE; MALE; MAZE TEST; NONHUMAN; RAT; SALIVATION;

EID: 34147208254     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296598     Document Type: Article

References (27)

1. Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002;60 (Suppl 5A):82-89.
2. Goyal RK. Muscarinic receptor subtypes. Physiology and clinical implications. New Engl J Med. 1989;321:1022-1029.
3. Eglen RM, Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol. 1996;78:59-68.
4. Andersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46-53.
5. 3 receptor selectivity. Eur Urology Suppl. 2002;1:23-28.
6. Siegler EL, Reidenberg M. Treatmet of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther. 2004; 75:484-488.
7. Katz IR, Sands LP, Bilker W, Difilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46:8-13.
8. Donnellan CA, Fook L, McDonald P, Playfer JR. Oxybutynin and cognitive dysfunction. BMJ. 1997;315:1363-1354.
9. 1 receptor subtypes and selectivity for urinary bladder over salivary gland-. Arzneimittel-Forschung (Drug Research). 2007;57(2):92-100.
10. Miyachi H, Kiyota H, Segawa M. Design, synthesis and antimuscarinic activity of some imidazolium derivatives. Bio Med Chem Lett. 1999;9:3003-3008.
11. Miyachi H, Kiyota H, Uchiki H, Segawa M. Synthesis and antimuscarinic activity of a series of 4-(1-imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents. Bio Med Chem. 1999;7: 1151-1161.
12. 3 subtype. Proc Natl Acad Sci. USA 2000;97:9579-9584.
13. 3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther. 2004;310:1255-1265.
14. Somogyi GT, de Groat WC. Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. J Auton Nerv Sys. 1992;37:89-98.
15. 2 inhibitory muscarinic receptors mediate rat bladder contractility. Am J Physiol. 1998; 274:R517-R523.
16. 3 muscarinic receptor single- and double-knockout mice. Mol Pharmacol. 2004;66:260-267.
17. McNamara RK, Skelon RW. The neuropharmacological and neurochemical basis of place learning in the Morris water mae. Brain Res Rev. 1993;18:33-49.
18. Zwagemakers JMA, Claassen V. Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 1: Antimuscarinic and spasmolytic effects. Arzneimittel-Forschung (Drug Research). 1980;30:1517-1525.
19. 3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991;256:562-567.
20. Igawa Y, Mattiasson A, Andersson K-E. Functional importance of cholinergic and purinergic neurotransmission for micturition contraction in the normal, unanaesthetized rat. Br J Pharmacol. 1993;109:473-479.
21. Hirose H, Aoki I, Kimura T, Fujikawa T, Numazawa T, Sasaki K et al. The subtypes of muscarinic receptors for neurogenic bladder contraction in rats. Eur J Pharmacol. 2002; 452:245-253.
22. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol. 1997;120:1409-1418.
23. Nilvebrant L, Andersson KE, Gillberg P-G, Stahl M, Sparf B. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 1997;327:195-207.
24. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther. 1995;273:959-966.
25. 3 receptors. J Urol. 2004;172:2460-2464.
26. Bockman CS, Bradley ME, Dang HK, Zeng W, Scofield MA, Dowd FJ. Molecular and pharmacological characterization of muscarinic receptor subtypes in a rat parotid gland cell line: comparison with native parotid gland. J Pharmacol Exp Ther. 2001;297:718-726.
27. Oka T, Nakano K, Kirimoto T, Matsuura N. Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats. Jpn J Pharmacol. 2001;87:27-33.